234 related articles for article (PubMed ID: 33973741)
1. Quantification of JAK2V617F mutation load by droplet digital PCR can aid in diagnosis of myeloproliferative neoplasms.
Zheng CF; Zhao XX; Chen XH; Liu Z; Wang WJ; Luo M; Ren Y; Wang HW
Int J Lab Hematol; 2021 Aug; 43(4):645-650. PubMed ID: 33973741
[TBL] [Abstract][Full Text] [Related]
2. Clinical Manifestations and Risk Factors for Complications of Philadelphia Chromosome-Negative Myeloproliferative Neoplasms.
Duangnapasatit B; Rattarittamrong E; Rattanathammethee T; Hantrakool S; Chai-Adisaksopha C; Tantiworawit A; Norasetthada L
Asian Pac J Cancer Prev; 2015; 16(12):5013-8. PubMed ID: 26163633
[TBL] [Abstract][Full Text] [Related]
3. The Combination of
Wu S; Luo P; Rouzi T; Yu Y; Xiong B; Wang Y; Zuo X
Cancer Control; 2023; 30():10732748231163648. PubMed ID: 36895113
[TBL] [Abstract][Full Text] [Related]
4. Coexisting JAK2V617F and CALR Exon 9 Mutations in Myeloproliferative Neoplasms - Do They Designate a New Subtype?
Ahmed RZ; Rashid M; Ahmed N; Nadeem M; Shamsi TS
Asian Pac J Cancer Prev; 2016; 17(3):923-6. PubMed ID: 27039813
[TBL] [Abstract][Full Text] [Related]
5. Clinical and laboratory significance of defective P2Y(12) pathway function in patients with myeloproliferative neoplasms: a pilot study.
Chang H; Shih LY; Michelson AD; Dunn P; Frelinger AL; Wang PN; Kuo MC; Lin TL; Wu JH; Tang TC
Acta Haematol; 2013; 130(3):181-7. PubMed ID: 23751441
[TBL] [Abstract][Full Text] [Related]
6. [Pathological characteristics of megakaryocytes in myeloproliferative neoplasms and their correlation with driver gene mutations].
Shi ZX; Zhang PH; Li B; Fang LH; Xu ZF; Qin TJ; Liu JQ; Hu NB; Pan LJ; Qu SQ; Liu D; Xiao ZJ
Zhonghua Xue Ye Xue Za Zhi; 2020 Oct; 41(10):798-805. PubMed ID: 33190435
[No Abstract] [Full Text] [Related]
7. [Clinical Analysis of 208 Patiets with BCR/ABL Negative Myeloproliferative Neoplasms].
Shen QH; Guo YJ; Xue CE; Wang Y; Lin FR
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Feb; 27(1):159-164. PubMed ID: 30738463
[TBL] [Abstract][Full Text] [Related]
8. The clinical significance of JAK2V617F mutation for Philadelphia-negative chronic myeloproliferative neoplasms in patients with splanchnic vein thrombosis.
Yonal I; Pinarbası B; Hindilerden F; Hancer VS; Nalcaci M; Kaymakoglu S; Diz-Kucukkaya R
J Thromb Thrombolysis; 2012 Oct; 34(3):388-96. PubMed ID: 22569900
[TBL] [Abstract][Full Text] [Related]
9. A highly specific q-RT-PCR assay to address the relevance of the JAK2WT and JAK2V617F expression levels and control genes in Ph-negative myeloproliferative neoplasms.
Fantasia F; Di Capua EN; Cenfra N; Pessina G; Mecarocci S; Rago A; Cotroneo E; Busanello A; Equitani F; Lo-Coco F; Nervi C; Cimino G
Ann Hematol; 2014 Apr; 93(4):609-16. PubMed ID: 24173087
[TBL] [Abstract][Full Text] [Related]
10. Impact of JAK2V617F Mutational Status on Phenotypic Features in Essential Thrombocythemia and Primary Myelofibrosis.
Yönal İ; Dağlar-Aday A; Akadam-Teker B; Yılmaz C; Nalçacı M; Yavuz AS; Sargın FD
Turk J Haematol; 2016 Jun; 33(2):94-101. PubMed ID: 25913509
[TBL] [Abstract][Full Text] [Related]
11. Immunophenotype of myeloid granulocytes in Chinese patients with BCR::ABL1-negative myeloproliferative neoplasms.
Liang F; Liang X; Pan L; Jin Q; Deng J; Hong M; Wei W; Hao Z; Ren H; Wang H; Chen X
Clin Exp Med; 2024 May; 24(1):106. PubMed ID: 38771542
[TBL] [Abstract][Full Text] [Related]
12. The impact of JAK2V617F mutation on Philadelphia-negative myeloproliferative neoplasms.
Şahin E; Yönal-Hindilerden İ; Hindilerden F; Aday A; Nalçacı M
Turk J Med Sci; 2022 Feb; 52(1):150-165. PubMed ID: 34482679
[TBL] [Abstract][Full Text] [Related]
13. Detection of MPL exon10 mutations in 103 Chinese patients with JAK2V617F-negative myeloproliferative neoplasms.
Chen X; Qi X; Tan Y; Xu Z; Xu A; Zhang L; Wang H
Blood Cells Mol Dis; 2011 Jun; 47(1):67-71. PubMed ID: 21555228
[TBL] [Abstract][Full Text] [Related]
14. The differential diagnosis of classical myeloproliferative neoplasms (MPN): the updated WHO criteria.
Kvasnicka HM
Rinsho Ketsueki; 2019; 60(9):1166-1175. PubMed ID: 31597840
[TBL] [Abstract][Full Text] [Related]
15. Thromboses and hemorrhages are common in MPN patients with high JAK2V617F allele burden.
Bertozzi I; Bogoni G; Biagetti G; Duner E; Lombardi AM; Fabris F; Randi ML
Ann Hematol; 2017 Aug; 96(8):1297-1302. PubMed ID: 28585070
[TBL] [Abstract][Full Text] [Related]
16. CALR, JAK2 and MPL mutation status in Argentinean patients with BCR-ABL1- negative myeloproliferative neoplasms.
Ojeda MJ; Bragós IM; Calvo KL; Williams GM; Carbonell MM; Pratti AF
Hematology; 2018 May; 23(4):208-211. PubMed ID: 28990497
[TBL] [Abstract][Full Text] [Related]
17. [A quantitative assay for JAK2 mutation in 135 patients with chronic myeloproliferative neoplasms].
Chao HY; Shen YM; Zhang R; Feng YF; Cen JN; Yao L; Shen HJ; Zhu ZL; Xue YQ
Zhonghua Xue Ye Xue Za Zhi; 2009 May; 30(5):321-5. PubMed ID: 19799128
[TBL] [Abstract][Full Text] [Related]
18. The effects of mutational profiles on phenotypic presentation of myeloproliferative neoplasm subtypes in Bosnia: 18 year follow-up.
Kurtovic-Kozaric A; Islamagic E; Komic H; Bilalovic N; Eminovic I; Burekovic A; Uzunovic A; Kurtovic S
Bosn J Basic Med Sci; 2020 May; 20(2):236-247. PubMed ID: 31668145
[TBL] [Abstract][Full Text] [Related]
19. Determination of accuracy of polycythemia vera diagnoses and use of the JAK2V617F test in the diagnostic scheme.
Roda P; Ferrari A; Tang X; Erlich P; Eisenhower C; Patel MD; Irvin-Barnwell EA
Ann Hematol; 2014 Sep; 93(9):1467-72. PubMed ID: 24687383
[TBL] [Abstract][Full Text] [Related]
20. CALR, JAK2, and MPL mutation profiles in patients with four different subtypes of myeloproliferative neoplasms: primary myelofibrosis, essential thrombocythemia, polycythemia vera, and myeloproliferative neoplasm, unclassifiable.
Kim SY; Im K; Park SN; Kwon J; Kim JA; Lee DS
Am J Clin Pathol; 2015 May; 143(5):635-44. PubMed ID: 25873496
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]